Anidulafungin
- Generic Name
- Anidulafungin
- Brand Names
- Ecalta, Eraxis
- Drug Type
- Small Molecule
- Chemical Formula
- C58H73N7O17
- CAS Number
- 166663-25-8
- Unique Ingredient Identifier
- 9HLM53094I
- Background
Anidulafungin or Eraxis is an anti-fungal drug manufactured by Pfizer that gained approval by the Food and Drug Administration (FDA) in February 21, 2006; it was previously known as LY303366. There is preliminary evidence that it has a similar safety profile to caspofungin.
- Indication
用于治疗食管念珠菌感染，念珠菌性败血症，念珠菌引起的腹腔脓肿及念珠菌性腹膜炎。
- Associated Conditions
- Bloodstream Infections (BSI), Candidemia, Candidiasis, Esophageal Candidiasis, Fungal peritonitis caused by Candida, Intraabdominal Abscess caused by Candida, Invasive Aspergillosis, Oropharyngeal Candidiasis
Study to Test the Combination of Voriconazole and Anidulafungin in Patients Who Have, or Are Thought to Have, Invasive Aspergillosis and Who Are Unable to Take a Common Antifungal Therapy (Polyene)
- First Posted Date
- 2008-02-21
- Last Posted Date
- 2010-02-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 6
- Registration Number
- NCT00620074
- Locations
- 🇺🇸
Pfizer Investigational Site, Fort Worth, Texas, United States
This Is An Open-Label, Non-Comparative Study Designed To Evaluate A Short Course Of IV Anidulafungin, Followed Optionally By Oral Voriconazole, For The Treatment Of Candidemia And Invasive Candidiasis
- Conditions
- CandidemiaInvasive Candidiasis
- Interventions
- First Posted Date
- 2007-10-23
- Last Posted Date
- 2011-01-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 54
- Registration Number
- NCT00548262
- Locations
- 🇵🇦
Pfizer Investigational Site, Panama, Panama
Anidulafungin In Treatment Of Candidemia In Asian Subjects
- First Posted Date
- 2007-10-01
- Last Posted Date
- 2010-03-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 43
- Registration Number
- NCT00537329
- Locations
- 🇹🇭
Pfizer Investigational Site, Amphoe Mueang, Khon Kaen, Thailand
Anidulafungin Plus Voriconazole Versus Voriconazole For The Treatment Of Invasive Aspergillosis
- First Posted Date
- 2007-09-18
- Last Posted Date
- 2012-04-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 459
- Registration Number
- NCT00531479
- Locations
- 🇬🇧
Pfizer Investigational Site, Manchester, United Kingdom
Study Will Evaluate The Safety And Efficacy Of Anidulafungin In Patients With Candidemia Or Invasive Candidiasis
- Conditions
- Candidiasis
- Interventions
- First Posted Date
- 2007-07-04
- Last Posted Date
- 2011-10-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 282
- Registration Number
- NCT00496197
- Locations
- 🇰🇷
Pfizer Investigational Site, Seoul, Korea, Republic of
Antimicrobial PK in Infants With Suspected or Confirmed Infection
- Conditions
- Infection
- Interventions
- First Posted Date
- 2007-06-26
- Last Posted Date
- 2012-11-19
- Lead Sponsor
- Duke University
- Target Recruit Count
- 450
- Registration Number
- NCT00491426
- Locations
- 🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸University of California at San Diego, La Jolla, California, United States
Anidulafungin in Treating Immunocompromised Children With Neutropenia
- Conditions
- InfectionNeutropeniaUnspecified Childhood Solid Tumor, Protocol Specific
- First Posted Date
- 2003-09-11
- Last Posted Date
- 2013-06-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00068471
- Locations
- 🇺🇸
Duke Comprehensive Cancer Center, Durham, North Carolina, United States
🇺🇸Lombardi Cancer Center at Georgetown University Medical Center, Washington, District of Columbia, United States
🇺🇸Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
Anidulafungin Versus Fluconazole in the Treatment of Candidemia
- Conditions
- CandidaCandidiasis
- First Posted Date
- 2003-04-11
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 248
- Registration Number
- NCT00058682
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
The Safety and Efficacy of Anidulafungin Versus Comparator in Patients With Candidemia and Invasive Candidiasis
- Conditions
- Candidiasis
- First Posted Date
- 2003-03-12
- Last Posted Date
- 2008-10-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 256
- Registration Number
- NCT00056368
- Locations
- 🇺🇸
Versicor, Inc., King of Prussia, Pennsylvania, United States
Safety, Tolerance and Pharmacokinetics of Anidulafungin in Immunocompromised Children Ages 2-17
- Conditions
- Neutropenia
- First Posted Date
- 2003-03-12
- Last Posted Date
- 2008-10-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 25
- Registration Number
- NCT00056381
- Locations
- 🇺🇸
Versicor, King of Prussia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.